Asymchem Laboratories (Tianjin) Co., Ltd. Class H (HK:6821)
:6821
Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$73.80
-HK$0.50(-1.06%)
At close: 4:00 PM EST
HK$73.80
-HK$0.50(-1.06%)
Day’s Range― - ―
52-Week RangeHK$67.15 - HK$116.60
Previous CloseN/A
Volume191.84K
Average Volume (3M)640.69K
Market Cap
HK$47.31B
Enterprise ValueHK$32.62B
Total Cash (Recent Filing)HK$7.78B
Total Debt (Recent Filing)HK$238.99M
Price to Earnings (P/E)39.0
Beta1.43
Next Earnings
Sep 01, 2026Next Dividend Ex-DateN/A
Dividend Yield1.57%
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$127.54Price Target Upside72.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.45
Revenue Forecast (FY)HK$9.22B
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low leverage provides durable financial flexibility: it lowers bankruptcy risk, supports multi-year capital allocation for capacity, R&D or M&A, and allows the firm to absorb demand volatility. Over a 2–6 month horizon this underpins ability to invest without immediate refinancing pressure.
CDMO Business ModelAs a contract development and manufacturing organization (CDMO), revenue is fee-based across development, scale-up and commercial supply phases. This business model creates multi-stage revenue streams and long-term customer relationships, generating durable demand as pharma pipelines and outsourcing trends persist.
Solid MarginsGross and net margins at these levels indicate meaningful pricing power and operational efficiency in specialty chemical and API manufacturing. Sustained mid/high-teens net margins provide capacity to reinvest in GMP capacity and quality systems, supporting steady profitability over the medium term.
Bears Say
Weak Cash ConversionThin FCF relative to net income and negative TTM free cash flow growth indicate earnings are not fully converting to cash. That reduces available internal funding for capex, dividends or deleveraging and increases sensitivity to working capital swings, limiting durable financial optionality.
Profitability Below Prior PeakA material step-down from earlier peak margins suggests structural normalization or emerging competitiveness/volume mix headwinds. Persistently lower margins would compress returns on invested capital and constrain earnings power relative to historical performance over the medium term.
Stepped-down ROEDeclining ROE signals reduced effectiveness in converting equity into profits. If ROE remains depressed, it limits shareholder return potential and can reflect lower utilization, pricing pressure, or higher investment without commensurate earnings—factors that weigh on long-term return prospects.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$67.15 and its highest was HK$116.60 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$47.31B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 88 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.963 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.963.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.202 which represents an annual dividend yield of 1.57%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.963 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went up 5.634%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
6.34%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$127.54
▲(72.82% Upside)
Technical Analysis
Genscript Biotech
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---